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Abstract
Clinical trials are critically important for the development of new cancer treatments. According to recent estimates, however, clinical
trial enrollment is only about 8%. Lack of patient understanding or awareness of clinical trials is one reason for the low rate of
participation. The purpose of this observational study was to evaluate the readability of cancer clinical trial websites designed to
educate the general public and patients about clinical trials. Nearly 90% of Americans use Google to search for health-related
information. We conducted a Google Chrome Incognito search in 2018 using the keywords “cancer clinical trial” and “cancer clinical
trials.” Content of the 100 cancer clinical trial websites was analyzed using an online readability panel consisting of Flesch-Kincaid
Grade Level, Flesch Reading Ease, Gunning-Fog Index, Coleman-Liau Index, and Simple Measure of Gobbledygook scales. Reading level
difficulty was assessed and compared between commercial versus non-commercial URL extensions. Content readability was found to
be “difficult” (10.7 grade level). No significant difference in readability, overall, and between commercial and non-commercial URL
extensions was found using 4/5 measures of readability; 90.9% of commercial versus 49.4% of non-commercial websites were written
at a >10th grade (P¼ .013) using Gunning-Fog Index. Written cancer clinical trials content on the Internet is written at a reading level
beyond the literacy capabilities of the average American reader. Improving readability to accommodate readers with basic literacy skills
will provide an opportunity for greater comprehension that could potentially result in higher rates of clinical trial enrollment.
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Introduction
Clinical trials are critically important for the development of
new cancer treatments; however, according to recent estimates,
clinical trial enrollment is only 8%, ranging from 6.3% to 7.0%
at community centers and between 14.0% and 15.9% at aca-
demic centers.1-3 Lack of awareness of and knowledge about
clinical trials is one of the major barriers to patient participa-
tion.4-6 To close this gap in understanding, many cancer centers
and clinical practices that offer clinical trials provide informa-
tion such as what clinical trials are, their purpose, types of
trials, the importance of considering trial participation, how
safety is ensured, what to expect when enrolled in a trial, and
how to join a trial to their patients through the most commonly
used source of health-related information—the Internet.7-9
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The National Institutes of Health (NIH) recommend that
health-related materials be written at the seventh- to eighth-
grade level10 to make information accessible to the approxi-
mately 43% of American adults who have basic or below basic
literacy skills.11 Additional considerations for effective written
communication, include the legibility of the material which
relates to typography; the comprehensibility or how well the
user can understand the intended meaning; and the readability
of the material, that is, the ease at which the text can be read
and understood.12 Comprehensibility and readability are per-
haps the most important aspects of communicating complex
written health-related material. Comprehensibility is more dif-
ficult to determine but readability can be assessed with a vari-
ety of formulas,13 each of which evaluate word and sentence
length using different weighting factors.14 Readability formu-
las are objective and quantitative in nature and estimate the
difficulty of written material by assessing a wide range of
content and prose styles. However, because no formula is
100% accurate, the use of more than 1 readability formula
when evaluating written content is preferable to improve the
validity of the results.15
Evaluation of online sources of cancer-related information
(eg, screening, treatment)16-19 has found that information is
written at reading levels above the sixth- or seventh-grade level
and thus beyond the ability of the average reader. An assess-
ment of 165 988 trials registered as ClinicalTrials.gov20
through 2014 reported that, on average, 18 years of education
(Master’s level) are needed to properly understand the trial
descriptions using 4 independent readability algorithms.20 A
review of the top 100 cancer clinical trial websites on Google
and Yahoo in 2005 found that the overwhelming amount and
diversity of information as well as the complex language used
was a deterrent to patients with cancer.21 Other examinations of
the readability of Internet-based information about clinical
trials has been confined to the understandability of recruitment
resources,22 eligibility criteria,23 and informed consent.24 The
purpose of this study was to evaluate the readability of cancer
clinical trial websites and replicate the experience of the aver-
age American searching for information about cancer clinical
trials using a systematic search of the top 100 clinical trial
websites available on Google Chrome Incognito in 2018 and
applying a panel of validated readability tests.
Methods
Google Chrome is the most commonly used search engine in
the United States and worldwide, accounting for 88.25% of the
search engine market share in the United States and 92.78%
around the world, followed by Bing (6.33% United States and
2.55% worldwide) and Yahoo (3.84% United States and 1.61%
worldwide).25 Using the Google Chrome Incognito web brow-
ser to assure generality of the returned results, the search terms
“cancer clinical trial” and “cancer clinical trials” were entered.
Unlike Google Chrome, Google Chrome Incognito does not
save browsing history, cookies, and site data and, therefore,
is not influenced by prior search history and cookies on the
device used to collect study data when displaying the search
results. The first 100 websites that were active in 2018, in the
English language, and that provided general information about
cancer clinical trials were included. Industry research indicates
that the first search engine results page (SERP) receives almost
95% of web traffic and the 67% of all clicks on the first page go
to the top 5 listings.26 Therefore, to include all possible cancer
clinical trial websites, we searched the first 20 SERPs which
yielded 100 websites. Excluded were websites that collected
contact information for the purpose of enrollment and search
sites to locate a cancer clinical trial based on the entry of
specific clinical criteria. The search was conducted by a single
researcher (G.C.H.).
To calculate the scores with the Flesch-Kincaid Grade Level
(FKGL), Flesch Reading Ease (FRE), Gunning-Fog Index
(GFI), Coleman-Liau (CLI), and Simple Measure of Gobble-
dygook (SMOG) tests, an online calculator,27 recommended by
the NIH28 and used in research by others when evaluating
online health information,29-33 was employed. The online read-
ability calculator evaluates the page found at the URL provided
using the series of readability formulas selected. The presenta-
tion of the text (eg, headings, bullets) is taken into account and
all material on the page is “read” which is consistent with the
manner in which a reader would view the site. Any pages
without text were excluded. In the case when a formatting error
was encountered, text was manually entered into the calculator
and scores were generated. To calculate scores, the FKGL and
FRE tests both utilize the average sentence length and average
syllables per word,34,35 whereas GFI assesses average sentence
length and the use of polysyllabic words.36 CLI calculates the
average number of letters per 100 words and the average sen-
tence length,37 and SMOG evaluates number of polysyllabic
words in 3 ten-sentence samples38 to determine the US aca-
demic grade level at which written material can be compre-
hended. The FRE is scored on a 100-point scale with scores of 0
to 29 considered “very confusing,” 30 to 49 “difficult,” 50 to 59
“fairly difficult,” 60 to 69 “standard” (eighth- and ninth-grade
level), 70 to 79 “fairly easy,” 80 to 89 “easy,” and 90 to 100
“very easy” (fifth-grade level) readability.39
Data Analysis
For each readability score, the minimum and maximum scores
were reported and the overall mean and standard deviation
(SD) were calculated. Websites were classified as non-
commercial or commercial based on the URL extension with
.org, .gov, and .edu coded as non-commercial and .com, .net, or
other coded as commercial. Scores for the FKGL, GFI, CLI,
and SMOG tests were recoded as “easy, <grade 6,”12 “average,
grade 6-10,” and “difficult or higher than grade 10.”29-33 Flesch
Reading Ease scores were grouped as 80 to 100¼ “easy,” 60 to
79 ¼ “average,” and 0 to 59 ¼ “difficult.” Differences in the
mean scores and grade level, overall, and between non-
commercial and commercial websites were computed using
Student t test and w2 test of association, respectively. Values
of P <.05 were considered statistically significant. All analyses
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were performed using IBM SPSS version 25.40 This study was
exempted from human subjects review by the Columbia
University Institutional Review Board.
Results
The mean grade level scores for all 5 tests ranged from 10.7
(SD: 1.9) to 12.9 (SD: 1.7); mean FRE was 41.5, indicating a
mean readability at the “difficult, grade >10” reading level
(Table 1). Six of the 100 websites analyzed were scored as
“easy, grade <6” using the GFI test. Of the 100 websites eval-
uated, 89 were categorized as noncommercial (.org, .gov, and
.edu) and 11 as commercial (.com, .net, and other) based on the
URL extension (Table 2). Overall, the mean readability scores
of noncommercial website and commercial sites did not differ
using each of the 5 measures. When evaluating grade level
differences, only 6 (6.7%) noncommercial websites and none
of the commercial websites were written at the “easy, grade
<6 level.” All websites categorized as noncommercial (range
10.7-12.2 grade level with FKGL, GFI, CLI, and SMOG; 41.8
with FRE) as well as those categorized as commercial (range
11.4-13.2 grade level with FKGL, GFI, CLI, and SMOG; 39.1
with FRE) by URL were written at a “difficult (grade >10)”
reading level. Only the GFI found a statistically significant
difference in the reading level between noncommercial and
commercial websites with 49.4% versus 90.9% scored as dif-
ficult (P ¼ .013), respectively.
Discussion
Our analysis of 100 English language cancer clinical trial web-
sites using a panel of 5 well-known readability tests demon-
strated that the majority of these websites are written at a mean
grade level well beyond the reading capabilities of the average
American reader. The mean readability level ranged from
grade 10.7 to 12.3 using FKGL, GFI, CLI, and SMOG and the
mean FRE score was 41.5; all scores are interpreted as
“difficult.” That much of the written information available on
the websites evaluated, overall, and when stratified by URL
(noncommercial vs commercial), may not be understandable
by a large proportion of the public suggests a systemic problem
with the communication of complex clinical trial information
to readers. Given that most patients and caregivers seeking
health information on the Internet are frequently attempting
to supplement information given by a care provider and use
Internet-acquired information as both a prologue and an epilo-
gue to the conversations held with their provider,41 difficult
readability of these cancer clinical trial websites represents a
missed opportunity to engage patients and their families and to
empower patients to make informed cancer treatment
decisions.
Websites have evolved over time from static sources of
information to dynamic applications that provide a broad range
of information. A study by Weinreich et al found that users
frequently browse webpages rapidly—even those with substan-
tial content, and, at most, the average web user reads 28% of
the words during a visit to any website.42 When those with
limited literacy skills seek information online, they are usually
looking for specific information and typically spend about only
15 seconds or less on a page.43 Internet users with limited
literacy and poor health literacy skills struggle to decode chal-
lenging words and have problems remembering their mean-
ings. They often try to read every word, particularly when
reading something very important, but also tend to skip words
or sections that are too difficult to read.43 Capturing the web
reader’s attention while conveying complex clinical trial infor-
mation in an understandable format to readers with basic lit-
eracy skills, therefore, poses a unique challenge to web writers.
In 2010, the federal government enacted the Plain Writing
Act requiring all federal agencies to use “plain language.” Plain
language is a style of communication that is clear and concise
to help readers find the information that they need and better
understand the information they find to meet their informa-
tional needs.44 Despite this mandate, readers continue to strug-
gle with government-created clinical trials text. For example,
the comprehensibility of clinical trial eligibility posted on Clin
icalTrials.gov used for recruitment purposes among a lay audi-
ence was evaluated by Kang et al.23 Due to the frequent use of
medical and technical jargon, the authors found that a college-
level reading ability was required to understand the clinical
trial eligibility text. An examination of the use of plain lan-
guage in a cancer clinical trial website/app by Schultz et al
found that the medically complex titles and descriptions of
clinical trials on online applications also presents an enormous
barrier to the general public.45 After creating plain language
versions of the cancer type and basic inclusion/exclusion cri-
teria of 10 trial descriptions and testing among 217 volunteers,
users showed better comprehension of the inclusion/exclusion
criteria but showed continued to experience challenges in com-
prehending the study treatment plan. Although plain language
descriptions can help users to understand the basics about clin-
ical trials, much work is still needed to effectively communi-
cate the treatment being studied to increase user
comprehension.45
In addition to clinical trial websites, other trial-related mate-
rials created for patients are often difficult to comprehend.
Table 1. Readability Characteristics of Cancer Clinical Trial
Websites.
Test






(Grade > 10) Mean (SD) Range
FKGL 0 55 45 10.7 (1.9) 6.7-16.3
GFI 6 40 54 10.9 (2.9) 1.3-18.9
CLI 0 17 83 12.9 (1.8) 9.9-17.5
SMOG 0 20 80 12.3 (1.7) 8.5-17.5
FREa 0 3 97 41.5 (11.8) 3.5-62.8
Abbreviations: CLI, Coleman-Liau; FKGL, Flesch-Kincaid Grade Level; FRE,
Flesch Reading Ease; GFI, Gunning-Fog Index; SD, standard deviation; SMOG,
Simple Measure of Gobbledygook.
aFRE scored on a scale of 0 to 100.
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Friedman et al assessed the readability of clinical trial recruit-
ment materials (38% print and 62% web-based materials) and
found the overall reading level was grade 11.7. Importantly,
web-based materials were significantly more likely to be writ-
ten at a higher grade level than printed materials.22 Storino et al
investigated the readability and accuracy of online pancreatic
cancer patient resources and found that websites devoted to
pancreatic cancer clinical trials had a median readability score
of 15.2 (interquartile range, 12.8-17.0, P ¼ .002).46 In addition
to other well-known barriers to clinical trial enrollment, the
difficulty in understanding clinical trial information likely con-
tributes to a lack of understanding about clinical trials and
unwillingness to participate.
As with any study, ours have certain limitations. All clinical
trial sites analyzed were identified using a Google search, the
primary search engine in the world.47 Those seeking informa-
tion about clinical trials, however, may use other engines such
as Bing or Yahoo that serve millions of search queries per day
and this may have influenced the selection of sites for this
study. An analysis of the transaction log of ClinicalTrials.gov
by Graham et al48 demonstrated that 69% of users begin their
search for information related to clinical trials using a search
engine despite the availability of high-quality domain-specific
resources. The top-referring site was Google with 41% of users
accessing clinical trial information in this way.48 This strategy,
therefore, results in sites/pages indexed by the search engine as
“most relevant” getting the most exposure and greatest number
of direct visits. All websites evaluated were written in English
and affiliated with organizations in the United States; therefore,
our findings may not be generalizable to clinical trial websites
outside the United States. Finally, we only examined readabil-
ity of cancer clinical trial websites. Other measures such as
cohesion, legibility, and comprehensibility were not evaluated
and may provide additional insight into the usefulness of online
information about cancer clinical trials.
Conclusion
We consider our findings to be an important contribution to the
literature given that the Internet is the most common source for
individuals to find health-related information and that current
rates of cancer clinical trial participation are low. Further, our
findings are consistent with that of others who examined
Internet-based clinical trial recruitment resources (eg, Clinical
Trials.gov and others), patient resources, clinical trial eligibil-
ity criteria, and informed consent and, similarly, found that a
high-grade level reading ability is required to comprehend clin-
ical trial information.22-24
Simplifying the readability of cancer clinical trials informa-
tion on the Internet to accommodate readers with basic literacy
skills and augmenting written materials with videos, pictures,
and FAQ sheets to actively engage patients in learning about
cancer clinical trials49 would assist in increasing the accessi-
bility of clinical trial information to nearly half of the US
population and provide an opportunity for greater understand-
ing that could potentially result in higher rates of enrollment
into clinical trials.
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